Close Menu

NEW YORK (GenomeWeb) – GenePOC announced today that its rapid molecular assay to detect group A Streptococcus has been granted clearance by the US Food and Drug Administration.

The test, which runs on GenePOC's Revogene instrument, is the third test from the Quebec City-based diagnostics developer to be FDA cleared. It uses throat swab samples and can report positive Strep A results in as little as 42 minutes, and negative results in 70 minutes without requirement for confirmation by bacterial culture, the firm said in a statement. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.